These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31378579)

  • 1. Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.
    Beulque Y; Deleu AL; Punie K; De Wever L; Baldewijns M; Caruso S; Couchy G; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2019 Oct; 17(5):e909-e912. PubMed ID: 31378579
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.
    Vitale MG; Baldessari C; Milella M; Buti S; Militello AM; Di Girolamo S; Fornarini G; Perri G; Basso U; Maruzzo M; Porta C; Cosmai L; Pipitone S; Cerma K; Cascinu S; Sabbatini R
    Clin Genitourin Cancer; 2019 Oct; 17(5):e903-e908. PubMed ID: 31375351
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review.
    Osmán-García I; Congregado-Ruiz CB; Lendínez-Cano G; Baena-Villamarin C; Conde-Sanchez JM; Medina-López RA
    Urol Int; 2020; 104(3-4):323-326. PubMed ID: 31914452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable response after interruption of nivolumab in patients with metastatic renal cell carcinoma: Is renal toxicity a marker to predict the benefit of nivolumab?
    Kus T; Aktas G
    J Oncol Pharm Pract; 2020 Jun; 26(4):1000-1004. PubMed ID: 31594517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.
    Tachibana H; Kondo T; Ishihara H; Takagi T; Tanabe K
    Clin Genitourin Cancer; 2019 Aug; 17(4):e772-e778. PubMed ID: 31101580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
    Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
    Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
    Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
    J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A CASE OF RENAL CELL CARCINOMA THAT ONCE NIVOLUMAB HAD BEEN EFFECTIVE IN METASTATIC LESION AND MADE PRIMARY TUMOR RESECTABLE].
    Tsukahara S; Nagatomi Y; Otsubo S; Hasegawa S
    Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):32-35. PubMed ID: 31956216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NICE guidance on nivolumab with ipilimumab for untreated advanced renal cell carcinoma.
    Adler AI; Brooke A; Elsada A; Landells L
    Lancet Oncol; 2019 Jul; 20(7):904-905. PubMed ID: 31103427
    [No Abstract]   [Full Text] [Related]  

  • 11. Fatal Acute Motor Axonal Neuropathy Induced by Nivolumab: A Case Report and Literature Review.
    Yildirim N; Gonen M; Balgetir F; Er MB
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1104-e1107. PubMed ID: 31471269
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
    Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
    PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor.
    Mollica V; Di Nunno V; Corcioni B; Fiorentino M; Nobili E; Schiavina R; Golfieri R; Brunocilla E; Ardizzoni A; Massari F
    Anticancer Drugs; 2018 Oct; 29(9):911-913. PubMed ID: 29916898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate.
    Eze C; Manapov F; Gratzke C; Schmidt-Hegemann NS; Jung A; Kirchner T; Heinemann V; Stief CG; Belka C; Boeck S
    Eur J Cancer; 2018 May; 95():109-111. PubMed ID: 29477368
    [No Abstract]   [Full Text] [Related]  

  • 15. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.
    Thibault C; Vano Y; Soulat G; Mirabel M
    Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497
    [No Abstract]   [Full Text] [Related]  

  • 16. Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma.
    Kubo T; Sugawara T; Shinkawa T; Kurisu T; Kouzen N; Tanaka T; Fukuta F; Yamasaki K; Sugita S; Matsuo K; Morita R; Hirohashi Y; Tsukahara T; Kanaseki T; Hasegawa T; Masumori N; Torigoe T
    Immunol Med; 2021 Jun; 44(2):136-141. PubMed ID: 32634346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eruptive keratoacanthomas secondary to nivolumab immunotherapy.
    Bednarek R; Marks K; Lin G
    Int J Dermatol; 2018 Mar; 57(3):e28-e29. PubMed ID: 29318617
    [No Abstract]   [Full Text] [Related]  

  • 18. A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab.
    Sekito T; Takamoto A; Kobayashi Y; Mitsui M; Watari S; Kubota R; Sadahira T; Iwata T; Nishimura S; Edamura K; Sako T; Araki M; Watanabe M; Watanabe T; Shibata R; Ennishi D; Nasu Y
    Acta Med Okayama; 2021 Jun; 75(3):397-402. PubMed ID: 34176946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma.
    Yu-Li Su H
    Clin Genitourin Cancer; 2018 Apr; 16(2):114-116. PubMed ID: 29329663
    [No Abstract]   [Full Text] [Related]  

  • 20. Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.
    Dizman N; Bergerot P; Bergerot C; Lanman RB; Raymond VM; Banks KC; Jones J; Pal SK
    Eur Urol; 2018 Feb; 73(2):308-310. PubMed ID: 28844598
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.